GlassScriptPhysician profile
Jed C Tompkins
NPI 1710249875
$1,476.05
in general payments reported to CMS, 2019-2025
21 companies · $404 in 2025
The $404 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $278 · 2020: $61.07 · 2022: $49.83 · 2023: $285 · 2024: $398 · 2025: $404.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,088.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,087.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $383.93 | 2019-2025 | Mounjaro, Zepbound, Emgality |
| Novo Nordisk INC | $213.51 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $128.34 | 2023-2025 | Vraylar, Ubrelvy |
| Glaxosmithkline, LLC. | $96.18 | 2019-2025 | Shingrix, Arexvy |
| Astellas Pharma US INC | $79.97 | 2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $64.89 | 2019-2025 | Xifaxan |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $62.02 | 2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.40 | 2019-2024 | Jardiance |
| Pfizer INC. | $54.78 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $48.06 | 2024 | Gemtesa |
| Exact Sciences Corporation | $45.00 | 2024 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $38.21 | 2023-2024 | Gardasil 9, M-M-R II, Vaxneuvance |
| Corcept Therapeutics | $35.03 | 2025 | Korlym |
| Axsome Therapeutics, INC. | $34.82 | 2024-2025 | Auvelity |
| Inspire Medical Systems, INC. | $30.62 | 2023 | Inspire |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $23.83 | 2019 | |
| Novartis Pharmaceuticals Corporation | $22.80 | 2019 | |
| Vanda Pharmaceuticals INC. | $17.32 | 2025 | Fanapt, Hetlioz |
| Allergan, INC. | $13.69 | 2020 | |
| Corium, LLC | $12.75 | 2023 | Azstarys |
| Amgen INC. | $11.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jed Tompkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.